FI112942B3 - Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi - Google Patents
Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksiInfo
- Publication number
- FI112942B3 FI112942B3 FI920749A FI920749A FI112942B3 FI 112942 B3 FI112942 B3 FI 112942B3 FI 920749 A FI920749 A FI 920749A FI 920749 A FI920749 A FI 920749A FI 112942 B3 FI112942 B3 FI 112942B3
- Authority
- FI
- Finland
- Prior art keywords
- alkyl
- aryl
- alkoxy
- substd
- halo
- Prior art date
Links
- DLYMRVCQTVOYEW-UHFFFAOYSA-N 1-(biphenyl-4-ylmethyl)-1h-imidazole Chemical group C1=CN=CN1CC(C=C1)=CC=C1C1=CC=CC=C1 DLYMRVCQTVOYEW-UHFFFAOYSA-N 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- -1 pivaloyloxymethyl Chemical group 0.000 abstract 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- YYYXAGYRXXVILU-UHFFFAOYSA-N 2-benzyl-1-phenylimidazole Chemical compound C=1C=CC=CC=1CC1=NC=CN1C1=CC=CC=C1 YYYXAGYRXXVILU-UHFFFAOYSA-N 0.000 abstract 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 abstract 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Phenolic Resins Or Amino Resins (AREA)
- Dental Preparations (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI955248A FI112941B (fi) | 1991-02-21 | 1995-11-02 | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1'-bifenyylijohdannaisten valmistamiseksi |
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2709891 | 1991-02-21 | ||
| JP2709891 | 1991-02-21 | ||
| JP9658891 | 1991-04-26 | ||
| JP9658891 | 1991-04-26 | ||
| JP13488991 | 1991-06-06 | ||
| JP13488991 | 1991-06-06 | ||
| JP16713891 | 1991-07-08 | ||
| JP16713891 | 1991-07-08 | ||
| JP17397291 | 1991-07-15 | ||
| JP17397291 | 1991-07-15 | ||
| JP18484191 | 1991-07-24 | ||
| JP18484191 | 1991-07-24 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI920749A0 FI920749A0 (fi) | 1992-02-20 |
| FI920749A FI920749A (fi) | 1992-08-22 |
| FI112942B FI112942B (fi) | 2004-02-13 |
| FI112942B3 true FI112942B3 (fi) | 2012-03-13 |
Family
ID=27549327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI920749A FI112942B3 (fi) | 1991-02-21 | 1992-02-20 | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi |
| FI955248A FI112941B (fi) | 1991-02-21 | 1995-11-02 | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1'-bifenyylijohdannaisten valmistamiseksi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI955248A FI112941B (fi) | 1991-02-21 | 1995-11-02 | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1'-bifenyylijohdannaisten valmistamiseksi |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP0545912B1 (fr) |
| JP (1) | JPH07121918B2 (fr) |
| KR (1) | KR0128289B1 (fr) |
| CN (3) | CN1045770C (fr) |
| AT (2) | ATE200778T1 (fr) |
| CA (2) | CA2229000C (fr) |
| CZ (1) | CZ289194B6 (fr) |
| DE (6) | DE122005000051I1 (fr) |
| DK (2) | DK0503785T3 (fr) |
| ES (2) | ES2156866T3 (fr) |
| FI (2) | FI112942B3 (fr) |
| GR (2) | GR3035906T3 (fr) |
| HK (2) | HK1011361A1 (fr) |
| HU (3) | HU223338B1 (fr) |
| IE (1) | IE920540A1 (fr) |
| IL (3) | IL114996A (fr) |
| IS (1) | IS1756B (fr) |
| LU (4) | LU91056I2 (fr) |
| NL (3) | NL300133I2 (fr) |
| NO (6) | NO304516B3 (fr) |
| NZ (1) | NZ241681A (fr) |
| PT (2) | PT545912E (fr) |
| RU (1) | RU2128173C1 (fr) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
| DE69329982T2 (de) * | 1992-06-02 | 2001-09-27 | Sankyo Co., Ltd. | 4-Carboxyimidazolderivate als Angiotensin-II-Antagonisten und ihre therapeutische Verwendung |
| JP3501484B2 (ja) * | 1992-12-17 | 2004-03-02 | 三共株式会社 | ビフェニル誘導体 |
| US5395844A (en) * | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
| NZ282485A (en) * | 1994-03-16 | 1997-06-24 | Sankyo Co | Treatment of ocular hypertension using imidazole derivatives |
| TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| AUPN786896A0 (en) | 1996-02-02 | 1996-02-29 | Telstra Corporation Limited | A network fault system |
| DK0930076T3 (da) * | 1996-07-15 | 2005-01-31 | Sankyo Co | Farmaceutiske præparater omfattende CS-866 og insulinresistensforbedrende midler og deres anvendelse i behandlingen af arteriosclerose og xanthom |
| AU5576498A (en) * | 1997-02-05 | 1998-08-26 | Sankyo Company Limited | Prophylactic or therapeutic agent for diabetic complication |
| US6713632B1 (en) | 1999-06-22 | 2004-03-30 | Takeda Chemical Industries, Ltd. | Process for the preparation of imidazole derivatives |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| PE20010781A1 (es) * | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
| JP4521844B2 (ja) * | 2000-04-18 | 2010-08-11 | 日本曹達株式会社 | ４，５−ジシアノイミダゾールの製造方法 |
| CA2420844A1 (fr) * | 2000-08-30 | 2003-02-28 | Sankyo Company, Limited | Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| KR100656716B1 (ko) | 2000-11-21 | 2006-12-13 | 상꾜 가부시키가이샤 | 의약 조성물 |
| MXPA04001878A (es) * | 2001-08-28 | 2004-06-15 | Sankyo Co | Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii. |
| JP3874419B2 (ja) | 2003-01-31 | 2007-01-31 | 三共株式会社 | 動脈硬化及び高血圧症の予防及び治療のための医薬 |
| CN1197866C (zh) * | 2003-03-21 | 2005-04-20 | 上海医药工业研究院 | 4，6－二氢呋喃并[3,4－d]咪唑－6－酮衍生物及其盐和制备方法 |
| TWI349549B (en) | 2003-04-15 | 2011-10-01 | Sankyo Co | Medicament for treatment of intraocular angiopoietic disease |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| GB0316546D0 (en) | 2003-07-15 | 2003-08-20 | Novartis Ag | Process for the manufacture of organic compounds |
| WO2005051298A2 (fr) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Nouvelles substances thyromimetiques contenant du phosphore |
| GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| JP2005206603A (ja) * | 2004-01-21 | 2005-08-04 | Teva Pharmaceutical Industries Ltd | カンデサルタンシレキセチルの調製 |
| GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
| EP1713795A2 (fr) | 2004-02-11 | 2006-10-25 | Teva Pharmaceutical Industries Ltd. | Polymorphes de candesartan cilexetil |
| US7157584B2 (en) | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
| TW200605867A (en) | 2004-03-17 | 2006-02-16 | Novartis Ag | Use of organic compounds |
| JP4511550B2 (ja) * | 2004-09-02 | 2010-07-28 | テバ ファーマシューティカル インダストリーズ リミティド | オルメサルタンメドキソミルの調製法 |
| KR20130048281A (ko) | 2004-10-08 | 2013-05-09 | 노파르티스 아게 | 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를 위한 레닌 억제제의 용도 |
| MX2007005129A (es) | 2004-10-27 | 2007-09-11 | Daiichi Sankyo Co Ltd | Compuesto de benceno que tiene 2 o mas sustituyentes. |
| JP2007525504A (ja) * | 2004-12-30 | 2007-09-06 | テバ ファーマシューティカル インダストリーズ リミティド | ２．５よりも高いｐＨでオルメサルタンメドキソミルを調製するための方法 |
| KR20090108739A (ko) * | 2005-01-03 | 2009-10-16 | 테바 파마슈티컬 인더스트리즈 리미티드 | 불순물의 양이 감소된 올메사탄 메독소밀 |
| WO2006115187A1 (fr) * | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | Produit pharmaceutique pour la prévention ou le traitement d'une maladie métabolique osseuse |
| EP1910343B1 (fr) | 2005-07-29 | 2014-10-29 | Krka | Procédé de préparation d'olmesartane medoxomil |
| EP1816131A1 (fr) * | 2006-02-06 | 2007-08-08 | KRKA, tovarna zdravil, d.d., Novo mesto | Procédé pour la préparation du olmesartan medoxomil |
| CZ299265B6 (cs) * | 2005-10-20 | 2008-05-28 | Zentiva, A. S. | Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu) |
| CZ299902B6 (cs) * | 2005-10-27 | 2008-12-29 | Zentiva, A. S | Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv |
| EP1801111B1 (fr) * | 2005-12-20 | 2014-07-16 | LEK Pharmaceuticals d.d. | Formes polymorphes du Olmesartan Medoxomil |
| EP1990052B1 (fr) | 2006-02-27 | 2012-05-16 | Takeda Pharmaceutical Company Limited | Emballage pharmaceutique comprenant du 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylate de (5-methyl-2-oxo-1,3-dioxol-4-yl)methyle ou du 2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylate de (5-methyl-2-oxo-1,3-dioxol-4-yl)methyle et un agent deshydratant |
| EP1891952B1 (fr) | 2006-05-04 | 2011-10-05 | LEK Pharmaceuticals d.d. | Composition pharmaceutique d'olmésartan médoxomil |
| US8048904B2 (en) * | 2006-06-19 | 2011-11-01 | Matrix Laboratories Ltd. | Process for the preparation of olmesartan medoxomil |
| WO2008096829A1 (fr) | 2007-02-07 | 2008-08-14 | Kyowa Hakko Kirin Co., Ltd. | Composés tricycliques |
| EP2481408A3 (fr) | 2007-03-01 | 2013-01-09 | Probiodrug AG | Nouvelle utilisation d'inhibiteurs glutaminyle cyclase |
| EP2141160A4 (fr) * | 2007-03-23 | 2011-06-29 | Daiichi Sankyo Co Ltd | Cristal moulu d'olmésartan médoxomil |
| EP2865670B1 (fr) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
| TWI448284B (zh) * | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| CN101311168B (zh) * | 2007-05-21 | 2010-12-08 | 上海医药工业研究院 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸酯的制备方法 |
| CN101311169B (zh) * | 2007-05-21 | 2011-03-16 | 上海医药工业研究院 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法 |
| US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
| CA3089569C (fr) | 2007-06-04 | 2023-12-05 | Synergy Pharmaceuticals Inc. | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| GB0710680D0 (en) * | 2007-06-05 | 2007-07-11 | Generics Uk Ltd | Novel crystalline form of olmesartan medoxmil |
| WO2009001661A1 (fr) * | 2007-06-22 | 2008-12-31 | Daiichi Sankyo Company, Limited | Agent médicamenteux pour la prévention ou le traitement de la maladie d'alzheimer |
| CN102083823B (zh) | 2008-06-09 | 2015-10-07 | 第一三共株式会社 | 1-联苯甲基咪唑化合物的制备方法 |
| EP2321341B1 (fr) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
| WO2010016549A1 (fr) | 2008-08-06 | 2010-02-11 | 協和発酵キリン株式会社 | Composé tricyclique |
| JP5395908B2 (ja) | 2008-11-17 | 2014-01-22 | 浙江海正薬業股▲ふん▼有限公司 | ４−（１−ヒドロキシ−１−メチルエチル）−２−プロピルイミダゾール−５−カルボン酸エステルの製造方法 |
| JP2009102340A (ja) * | 2008-12-04 | 2009-05-14 | Daiichi Sankyo Co Ltd | イミダゾール誘導体の製造法（２） |
| WO2010093601A1 (fr) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees |
| EP2426127B1 (fr) | 2009-04-28 | 2019-09-04 | Daiichi Sankyo Company, Limited | Nouveaux cristaux solvates |
| EP2426126B1 (fr) | 2009-04-28 | 2014-11-19 | Daiichi Sankyo Company, Limited | Procédé de production de l'olmésartan médoxomil |
| US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
| CN102050816A (zh) * | 2009-10-28 | 2011-05-11 | 北京万全阳光医学技术有限公司 | 一种合成奥美沙坦酯的方法 |
| HUP0900788A2 (en) | 2009-12-16 | 2011-11-28 | Sanofi Aventis | Process for producing 4-bromomethyl-biphenyl derivatives |
| WO2011083112A2 (fr) | 2010-01-05 | 2011-07-14 | Ratiopharm Gmbh | Forme posologique orale solide contenant de l'olmésartan médoxomil |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| EP2545047B9 (fr) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5) |
| EP2560953B1 (fr) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibiteurs de glutaminyl cyclase |
| JP5137996B2 (ja) * | 2010-04-28 | 2013-02-06 | 日本曹達株式会社 | ４，５−ジシアノイミダゾールの製造方法 |
| IT1400311B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
| EP2425859A1 (fr) | 2010-08-08 | 2012-03-07 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Formulations de l'olmesartane |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CN102206208A (zh) * | 2010-12-24 | 2011-10-05 | 上海现代制药股份有限公司 | 含低水平杂质的奥美沙坦酯的制备方法 |
| CN102060778B (zh) * | 2010-12-24 | 2012-05-23 | 江苏江神药物化学有限公司 | 一种4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的合成方法 |
| JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| WO2013018899A1 (fr) | 2011-08-03 | 2013-02-07 | 協和発酵キリン株式会社 | Dérivé de dibenzooxépine |
| BR112014014527A2 (pt) | 2011-12-15 | 2017-06-13 | Takeda Pharmaceuticals Usa Inc | combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros |
| CN103304550B (zh) * | 2012-03-16 | 2016-01-27 | 湖南欧亚生物有限公司 | 一种奥美沙坦酯的制备方法 |
| CN104583185A (zh) | 2012-08-31 | 2015-04-29 | 株式会社Api | 联芳基化合物的制造方法 |
| JP5881837B2 (ja) | 2012-09-26 | 2016-03-09 | 株式会社エーピーアイ コーポレーション | テトラゾール化合物の脱保護方法 |
| US9486503B2 (en) | 2012-10-04 | 2016-11-08 | Shionogi & Co., Ltd. | Medicinal agent for suppressing malignant tumor metastasis |
| CN103012382B (zh) * | 2012-12-05 | 2016-10-05 | 迪沙药业集团有限公司 | 一种奥美沙坦酯的制备方法 |
| CN103044407A (zh) * | 2012-12-20 | 2013-04-17 | 安徽悦康凯悦制药有限公司 | 奥美沙坦酯的制备方法 |
| CN103965167A (zh) * | 2013-01-29 | 2014-08-06 | 通化济达医药有限公司 | 咪唑羧酸衍生物 |
| JP2014152127A (ja) * | 2013-02-06 | 2014-08-25 | Tokuyama Corp | オルメサルタンメドキソミルの製造方法 |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| EP2970384A1 (fr) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
| RS65632B1 (sr) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Ltd | Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe |
| ES2847904T3 (es) | 2013-07-23 | 2021-08-04 | Daiichi Sankyo Co Ltd | Medicamento para la prevención o el tratamiento de la hipertensión |
| CN103880825B (zh) * | 2014-03-14 | 2019-03-05 | 浙江华海药业股份有限公司 | 一种高纯的三苯甲基奥美沙坦酯的制备工艺 |
| CN104356069B (zh) * | 2014-11-18 | 2016-09-14 | 黄冈鲁班药业有限公司 | 奥美沙坦酯中间体4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯的制备方法及应用 |
| CN104447564B (zh) * | 2014-11-24 | 2016-08-31 | 广州天赐高新材料股份有限公司 | 高纯度4,5-二氰基-2-三氟甲基咪唑及其盐的制备方法 |
| CN104402873A (zh) * | 2014-12-02 | 2015-03-11 | 千辉药业（安徽）有限责任公司 | 一种奥美沙坦酯中间体的制备方法 |
| CN105481842A (zh) * | 2015-12-15 | 2016-04-13 | 江苏中邦制药有限公司 | 一种奥美沙坦酯的制备方法 |
| EP3434284A4 (fr) | 2016-03-24 | 2019-11-13 | Daiichi Sankyo Company, Limited | Médicament pour le traitement d'une maladie rénale |
| CN106749195A (zh) * | 2016-12-30 | 2017-05-31 | 青岛黄海制药有限责任公司 | 一种奥美沙坦酯中间体杂质合成、鉴定的方法 |
| CN107474042A (zh) * | 2017-09-07 | 2017-12-15 | 浙江华海致诚药业有限公司 | 一种三苯甲基奥美沙坦酯的晶型h |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| CN109081812B (zh) * | 2018-08-30 | 2022-08-16 | 黄冈鲁班药业股份有限公司 | 4-(1-羟基-1-甲基乙基)-2-丙基咪唑-5-羧酸乙酯一水合物 |
| KR102131359B1 (ko) | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
| CN112778209B (zh) * | 2019-11-04 | 2024-05-14 | 宜昌东阳光长江药业股份有限公司 | 一种二酸的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5671074A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| JPS5671073A (en) | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| IE802177L (en) | 1980-10-21 | 1981-05-12 | Takeda Chemical Industries Ltd | Imidazol-5-ylacetic acid derivatives |
| US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
| CA1334092C (fr) | 1986-07-11 | 1995-01-24 | David John Carini | Imidazoles bloquant les recepteurs de l'angiotensine ii |
| US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| CA1338238C (fr) | 1988-01-07 | 1996-04-09 | David John Carini | Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens |
| US4916129A (en) | 1989-01-19 | 1990-04-10 | E. I. Du Pont De Nemours And Company | Combination β-blocking/angiotensin II blocking antihypertensives |
| EP0400835A1 (fr) | 1989-05-15 | 1990-12-05 | Merck & Co. Inc. | Benzimidazoles substitués comme antagoniste d'angiotensine II |
| IE64514B1 (en) | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
| JPH05504359A (ja) * | 1990-02-13 | 1993-07-08 | メルク・エンド・カムパニー・インコーポレーテツド | 置換ベンジル部分を含むイミダゾールアンギオテンシン２拮抗物質 |
| US5140037A (en) * | 1990-03-20 | 1992-08-18 | E. I. Du Pont De Nemours And Company | Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
-
1992
- 1992-02-20 CA CA002229000A patent/CA2229000C/fr not_active Expired - Lifetime
- 1992-02-20 CA CA002061607A patent/CA2061607C/fr not_active Expired - Lifetime
- 1992-02-20 IE IE054092A patent/IE920540A1/en active Protection Beyond IP Right Term
- 1992-02-20 FI FI920749A patent/FI112942B3/fi not_active IP Right Cessation
- 1992-02-20 IS IS3819A patent/IS1756B/is unknown
- 1992-02-21 HU HU9200578A patent/HU223338B1/hu active Protection Beyond IP Right Term
- 1992-02-21 AT AT93200195T patent/ATE200778T1/de active
- 1992-02-21 ES ES93200195T patent/ES2156866T3/es not_active Expired - Lifetime
- 1992-02-21 IL IL114996A patent/IL114996A/xx not_active IP Right Cessation
- 1992-02-21 PT PT93200195T patent/PT545912E/pt unknown
- 1992-02-21 EP EP93200195A patent/EP0545912B1/fr not_active Expired - Lifetime
- 1992-02-21 DE DE200512000051 patent/DE122005000051I1/de active Pending
- 1992-02-21 RU RU95101430A patent/RU2128173C1/ru active
- 1992-02-21 CZ CS1992516A patent/CZ289194B6/cs not_active IP Right Cessation
- 1992-02-21 PT PT92301449T patent/PT503785E/pt unknown
- 1992-02-21 AT AT92301449T patent/ATE200777T1/de active
- 1992-02-21 NZ NZ241681A patent/NZ241681A/en not_active IP Right Cessation
- 1992-02-21 DE DE122011000011C patent/DE122011000011I1/de active Pending
- 1992-02-21 DE DE2002199043 patent/DE10299043I2/de active Active
- 1992-02-21 KR KR1019920002676A patent/KR0128289B1/ko not_active IP Right Cessation
- 1992-02-21 NO NO19920688A patent/NO304516B3/no not_active IP Right Cessation
- 1992-02-21 DK DK92301449T patent/DK0503785T3/da active
- 1992-02-21 ES ES92301449T patent/ES2157895T7/es active Active
- 1992-02-21 DK DK93200195T patent/DK0545912T3/da active
- 1992-02-21 EP EP92301449A patent/EP0503785B3/fr not_active Expired - Lifetime
- 1992-02-21 DE DE69231798T patent/DE69231798T3/de not_active Expired - Lifetime
- 1992-02-21 IL IL10103492A patent/IL101034A/en not_active IP Right Cessation
- 1992-02-21 DE DE122009000024C patent/DE122009000024I1/de active Pending
- 1992-02-21 JP JP4034970A patent/JPH07121918B2/ja not_active Expired - Lifetime
- 1992-02-21 CN CN92102075A patent/CN1045770C/zh not_active Expired - Lifetime
- 1992-02-21 DE DE69231801T patent/DE69231801T2/de not_active Expired - Lifetime
-
1994
- 1994-10-28 HU HU9601179A patent/HU223667B1/hu active IP Right Grant
-
1995
- 1995-06-29 HU HU95P/P00605P patent/HU211934A9/hu unknown
- 1995-08-18 IL IL11499695A patent/IL114996A0/xx unknown
- 1995-11-02 FI FI955248A patent/FI112941B/fi not_active IP Right Cessation
- 1995-11-09 NO NO954507A patent/NO304517B1/no not_active IP Right Cessation
-
1997
- 1997-12-24 CN CN97126347A patent/CN1121859C/zh not_active Expired - Lifetime
- 1997-12-24 CN CN97123452A patent/CN1101384C/zh not_active Expired - Lifetime
-
1998
- 1998-11-26 HK HK98112355A patent/HK1011361A1/xx not_active IP Right Cessation
- 1998-12-09 HK HK98113006A patent/HK1011969A1/xx not_active IP Right Cessation
-
2001
- 2001-05-22 GR GR20010400760T patent/GR3035906T3/el unknown
- 2001-05-22 GR GR20010400763T patent/GR3035909T3/el unknown
-
2003
- 2003-08-01 NL NL300133C patent/NL300133I2/nl unknown
- 2003-11-27 NO NO2003009C patent/NO2003009I2/no unknown
-
2004
- 2004-01-26 LU LU91056C patent/LU91056I2/fr unknown
-
2006
- 2006-03-30 NL NL300227C patent/NL300227I1/nl unknown
- 2006-10-09 NO NO2006012C patent/NO2006012I1/no unknown
-
2007
- 2007-04-02 LU LU91330C patent/LU91330I2/fr unknown
-
2009
- 2009-02-13 NL NL300375C patent/NL300375I1/nl unknown
- 2009-05-11 LU LU91571C patent/LU91571I2/fr unknown
- 2009-09-11 NO NO2009019C patent/NO2009019I1/no unknown
-
2011
- 2011-07-26 LU LU91847C patent/LU91847I2/fr unknown
- 2011-08-10 NO NO2011013C patent/NO2011013I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI112942B3 (fi) | Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi | |
| PT91435A (pt) | Processo para a preparacao de aril-alquil-aminas e -amidas possuindo propriedades anticonvulsivas e neuroprotectoras e de composicoes farmaceuticas que as contem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20040002 |
|
| SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20060012 |
|
| PC | Transfer of assignment of patent |
Owner name: DAIICHI SANKYO COMPANY LIMITED Free format text: DAIICHI SANKYO COMPANY LIMITED |
|
| SPCG | Supplementary protection certificate granted | ||
| SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: C20110023 |
|
| SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: 328 Extension date: 20170220 |
|
| MA | Patent expired |